FDA Puts Hold on Experimental Pain Drug

The Food and Drug Administration has placed a clinical hold on Johnson & Johnson's nerve growth factor inhibitor drug fulranumab due to a possible association with a condition that could lead to a need for total joint replacements, according to a Reuters news report.

The drug was developed to block nerve growth factor, a protein associated with pain. Johnson & Johnson's fulranumab was not the only product to be placed on clinical hold due to a possible link to a bone disorder that would require a total joint replacement. Regeneron Pharmaceuticals has also had its pain drug for osteoarthritis put on hold.

Read the news report about the FDA's hold on Johnson & Johnson's fulranumab.

Read other coverage about the FDA:

- New Test Measuring DNA Methylation Levels Could Help Detect CRC

- Pharmaceutical Companies Submit Pain Management Drug to FDA

- FDA Accepts Drug Application for Postsurgical Pain Management


Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Articles We Think You'll Like

 

Featured Whitepapers

Featured Webinars